VCV001981100.6 - ClinVar

NM_004820.5(CYP7B1):c.788T>G (p.Val263Gly)

Germline

Classification

The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.

(3)

Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.

Conflicting classifications of pathogenicity
Likely pathogenic(2); Uncertain significance(1)

criteria provided, conflicting classifications

Somatic

No data submitted for somatic clinical impact

Somatic

No data submitted for oncogenicity

Variant Details

Identifiers

NM_004820.5(CYP7B1):c.788T>G (p.Val263Gly)

Variation ID: 1981100 Accession: VCV001981100.6

Type and length

single nucleotide variant, 1 bp

Location

Cytogenetic: 8q12.3 8: 64615753 (GRCh38) [ NCBI UCSC ] 8: 65528310 (GRCh37) [ NCBI UCSC ]

Timeline in ClinVar

	First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.	Last submission Help The date of the most recent submission for each type of classification for this variant.	Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline	Feb 8, 2023	Jan 25, 2025	Mar 4, 2024

HGVS

Nucleotide	Protein	Molecular consequence
NM_004820.5:c.788T>G MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.	NP_004811.1:p.Val263Gly	missense
NM_001324112.2:c.788T>G	NP_001311041.1:p.Val263Gly	missense
NM_004820.3:c.788T>G
NC_000008.11:g.64615753A>C
NC_000008.10:g.65528310A>C
NG_008338.2:g.188039T>G

... more HGVS ... less HGVS

Protein change

V263G

Other names

Canonical SPDI

NC_000008.11:64615752:A:C

Functional consequence Help The effect of the variant on RNA or protein function, based on experimental evidence from submitters.

Global minor allele frequency (GMAF) Help The global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.

Allele frequency Help The frequency of the allele represented by this VCV record.

Links

ClinGen: CA371334967 VarSome

Genes

Gene	OMIM	ClinGen Gene Dosage Sensitivity Curation		Variation Viewer Help Links to Variation Viewer, a genome browser to view variation data from NCBI databases.	Related variants
Gene	OMIM	HI score Help The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team.	TS score Help The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team.		Within gene Help The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants.	All Help The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene.
CYP7B1		-	-	GRCh38 GRCh37	529	583

Conditions - Germline

Condition Help The condition for this variant-condition (RCV) record in ClinVar.	Classification Help The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions)	Review status Help The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status.	Last evaluated Help The most recent date that a submitter evaluated this variant for the condition.	Variation/condition record Help The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page.
Spastic paraplegia	Likely pathogenic (1)	criteria provided, single submitter	May 26, 2022	RCV002780414.3
Inborn genetic diseases	Likely pathogenic (1)	criteria provided, single submitter	Mar 4, 2024	RCV003269278.3
Congenital bile acid synthesis defect 3 Hereditary spastic paraplegia 5A	Uncertain significance (1)	criteria provided, single submitter	Jan 23, 2024	RCV005044972.1

Submissions - Germline

Classification Help The submitted germline classification for each SCV record. (Last evaluated)	Review status Help Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria)	Condition Help The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant.	Submitter Help The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar.	More information Help This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter.
Likely pathogenic (May 26, 2022)	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015)) Method: clinical testing	Spastic paraplegia Affected status: unknown Allele origin: germline	Labcorp Genetics (formerly Invitae), Labcorp Accession: SCV003022481.2 First in ClinVar: Feb 07, 2023 Last updated: Feb 28, 2024	Comment: In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has … (more) In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This variant has not been reported in the literature in individuals affected with CYP7B1-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.0009%). This sequence change replaces valine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 263 of the CYP7B1 protein (p.Val263Gly). (less)
Likely pathogenic (Mar 04, 2024)	criteria provided, single submitter (Ambry Variant Classification Scheme 2023) Method: clinical testing	Inborn genetic diseases Affected status: unknown Allele origin: germline	Ambry Genetics Accession: SCV003980513.3 First in ClinVar: Jul 08, 2023 Last updated: May 01, 2024	Comment: The c.788T>G (p.V263G) alteration is located in exon 3 (coding exon 3) of the CYP7B1 gene. This alteration results from a T to G substitution … (more) The c.788T>G (p.V263G) alteration is located in exon 3 (coding exon 3) of the CYP7B1 gene. This alteration results from a T to G substitution at nucleotide position 788, causing the valine (V) at amino acid position 263 to be replaced by a glycine (G). Based on data from gnomAD, the G allele has an overall frequency of 0.001% (1/250916) total alleles studied. The highest observed frequency was 0.001% (1/113296) of European (non-Finnish) alleles. This variant has been identified in trans with another CYP7B1 variant in an individual with features consistent with CYP7B1-related spastic paraplegia (external communication). This amino acid position is not well conserved in available vertebrate species. The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as likely pathogenic. (less)
Uncertain significance (Jan 23, 2024)	criteria provided, single submitter (ACMG Guidelines, 2015) Method: clinical testing	Hereditary spastic paraplegia 5A Congenital bile acid synthesis defect 3 Explanation for multiple conditions: Uncertain. The variant was classified for several related diseases, possibly a spectrum of disease; the variant may be associated with one or more the diseases. Affected status: unknown Allele origin: germline	Fulgent Genetics, Fulgent Genetics Accession: SCV005677273.1 First in ClinVar: Jan 25, 2025 Last updated: Jan 25, 2025

Comment:

In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This variant has not been reported in the literature in individuals affected with CYP7B1-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.0009%). This sequence change replaces valine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 263 of the CYP7B1 protein (p.Val263Gly).

Comment:

The c.788T>G (p.V263G) alteration is located in exon 3 (coding exon 3) of the CYP7B1 gene. This alteration results from a T to G substitution at nucleotide position 788, causing the valine (V) at amino acid position 263 to be replaced by a glycine (G). Based on data from gnomAD, the G allele has an overall frequency of 0.001% (1/250916) total alleles studied. The highest observed frequency was 0.001% (1/113296) of European (non-Finnish) alleles. This variant has been identified in trans with another CYP7B1 variant in an individual with features consistent with CYP7B1-related spastic paraplegia (external communication). This amino acid position is not well conserved in available vertebrate species. The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as likely pathogenic.

Germline Functional Evidence

There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar.

Comment:

Citations for germline classification of this variant

There are no citations for germline classification of this variant in ClinVar. If you know of citations for this variation, please consider submitting that information to ClinVar.

Text-mined citations for this variant ...

Record last updated Feb 01, 2025

ClinVar Genomic variation as it relates to human health

NM_004820.5(CYP7B1):c.788T>G (p.Val263Gly)

Variant Details

Genes

Conditions - Germline

Submissions - Germline

Germline Functional Evidence

Citations for germline classification of this variant

Text-mined citations for this variant ...